NASDAQ : VCEL
Vericel Corporation — Key statistics
Healthcare · Biotechnology · United States
Last price 40.26 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 2.06B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 2.06B |
| Enterprise Value | 1.99B |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 5, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 51.21M |
| Shares Outstanding | 51.21M |
| Shares Change (YoY) | +0.01% |
| Shares Change (QoQ) | +3.03% |
| Owned by Insiders (%) | 1.19% |
| Owned by Institutions (%) | 110.78% |
| Float | 50.58M |
Ratios
| Measure | Value |
|---|
| PE Ratio | 85.78 |
| Forward PE | 60.62 |
| PS Ratio | 6.73 |
| Forward PS | 5.71 |
| PB Ratio | 5.57 |
| P/TBV Ratio | 5.65 |
| P/FCF Ratio | 33.43 |
| P/OCF Ratio | 29.59 |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | 82.25 |
| EV / Sales | 6.50 |
| EV / EBITDA | 63.95 |
| EV / EBIT | 109.25 |
| EV / FCF | 32.31 |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 5.04 |
| Quick Ratio | 4.53 |
| Debt / Equity | 0.25 |
| Debt / EBITDA | 2.16 |
| Debt / FCF | 1.51 |
| Interest Coverage | 28.49 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | 7.16% |
| Return on Assets (ROA) | 2.43% |
| Return on Invested Capital (ROIC) | 5.81% |
| Return on Capital Employed (ROCE) | 4.05% |
| Weighted Average Cost of Capital (WACC) | 9.66% |
| Revenue Per Employee | $769,606 |
| Profits Per Employee | $60,857 |
| Employee Count | 398 |
| Asset Turnover | 0.65 |
| Inventory Turnover | 4.43 |
Taxes
| Measure | Value |
|---|
| Income Tax | 859,000 |
| Effective Tax Rate | 3.43% |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 1.06 |
| 52-Week Price Change | +15.42% |
| 50-Day Moving Average | 40.58 |
| 200-Day Moving Average | 38.65 |
| Relative Strength Index (RSI) | 46.16 |
| Average Volume (20 Days) | 562,311 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 5.24M |
| Short Previous Month | 5.20M |
| Short % of Shares Out | 10.23% |
| Short % of Float | 10.36% |
| Short Ratio (days to cover) | 9.42 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 306.30M |
| Gross Profit | 228.38M |
| Operating Income | 18.24M |
| Pretax Income | 25.08M |
| Net Income | 24.22M |
| EBITDA | 31.15M |
| EBIT | 18.24M |
| Earnings Per Share (EPS) | $0.47 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 162.46M |
| Total Debt | 93.13M |
| Net Cash | 69.33M |
| Net Cash Per Share | $1.35 |
| Equity (Book Value) | 370.04M |
| Book Value Per Share | 7.23 |
| Working Capital | 212.20M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | 69.67M |
| Capital Expenditures | -8.01M |
| Depreciation & Amortization | 12.92M |
| Net Borrowing | n/a |
| Free Cash Flow | 61.66M |
| FCF Per Share | $1.20 |
Margins
| Measure | Value |
|---|
| Gross Margin | 74.56% |
| Operating Margin | 5.95% |
| Pretax Margin | 8.19% |
| Profit Margin | 7.91% |
| EBITDA Margin | 10.17% |
| EBIT Margin | 5.95% |
| FCF Margin | 20.13% |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -0.01% |
| Shareholder Yield | -0.01% |
| Earnings Yield | 1.17% |
| FCF Yield | 2.99% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $59.71 |
| Price Target Difference | 48.39% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 8 |
| Revenue Growth Forecast (3Y) | 18.09% |
| EPS Growth Forecast (3Y) | 57.07% |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | Oct 16, 2013 |
| Split Type | Reverse |
| Split Ratio | 1:20 |
Scores
| Measure | Value |
|---|
| Altman Z-Score | 8.42 |
| Piotroski F-Score | 7 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside | |